coeptistx.com - נכסים נקיים למניה בודדת COEP

Coeptis Therapeutics (COEP) business is independent of GDP fluctuations, relying on stable demand in oncology. Innovations in NK cells and alliances with pharma behemoths drive the growth of quotes, while production is based on external outsourcing. This chart on GURU.Markets displays the book value per share, where the 2.97 metric determines this valuation level.

Book value per share reflects the portion of equity attributable to a single security, allowing for an assessment of the real value of net assets regardless of market fluctuations. By analyzing the aggregate book value per share, an investor can evaluate the capitalization of the intellectual property of Coeptis Therapeutics (COEP), where the value of cell technology patents will serve as the foundation for future monopoly pricing power in oncohematology.